Aino Kalervo
Chief Executive Officer
Aino Kalervo, Chief Executive Officer of Tiltbio USA, joined TILT Biotherapeutics Oy in 2015. Over the years, she has held senior leadership roles including Chief Business Officer and Chief Operating Officer, playing a key role in the company’s first pharmaceutical collaborations as well as its Series A and B financing rounds. Since 2022, she has also served as President of TILT Biotherapeutics’ affiliate for U.S. clinical operations. As transition CEO, she now leads the effort to spin out the company’s lead asset into a new U.S.-based entity, Tiltbio Inc.
Prior to joining TILT Biotherapeutics, she held roles at Sanofi in Paris, focusing on strategy and business intelligence for biologics, with an emphasis on viral vectors, and at Theravectys as Director of Competitive Intelligence for lentiviral and CAR-T platforms. She began her career in preclinical R&D at Pfizer in Ann Arbor.
Aino holds an MSc in Molecular Biology from Eastern Michigan University and an MS in Strategy and Management of the Pharmaceutical Industry from ESSEC Business School.
